brandadmin

About brandadmin

This author has not yet filled in any details.
So far brandadmin has created 6 blog entries.

IVERIC bio Announces the Addition of Ophthalmic Industry Leader, Adrienne L. Graves, Ph.D., Former Chief Executive Officer of Santen Inc., to Its Board of Directors

By |2019-02-11T13:21:25+00:00Jan 31, 2019 |Uncategorized|

NEW YORK--(BUSINESS WIRE)--Dec. 12, 2018-- IVERIC bio Corporation (NASDAQ:ISEE) announced today the election ofAdrienne L. Graves, Ph.D., former Chief Executive Officer of Santen Inc., the U.S. arm of Japan’s largest ophthalmic pharmaceutical company, to its Board of Directors, effective immediately. Dr. Graves is well-known in the ophthalmology community and for her successful track record in building organizations

IVERIC bio Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference

By |2019-02-11T13:21:41+00:00Jan 3, 2019 |Uncategorized|

NEW YORK--(BUSINESS WIRE)--Jan. 3, 2019-- IVERIC bio Corporation (NASDAQ: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). Investors and the general public are invited to listen to a live webcast

IVERIC bio Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directors PDF Version Dr. Roberts is Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University

By |2019-02-11T13:21:48+00:00Jan 2, 2019 |Uncategorized|

NEW YORK--(BUSINESS WIRE)--Jan. 2, 2019-- IVERIC bio Corporation (NASDAQ: ISEE) announced today the election of Calvin (Cal) W. Roberts, M.D., Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of January 1. Dr. Roberts brings over 25 years

IVERIC bio Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration

By |2019-02-11T13:21:53+00:00Nov 12, 2018 |Uncategorized|

NEW YORK--(BUSINESS WIRE)--Nov. 12, 2018-- IVERIC bio Corporation (NASDAQ:ISEE) today announced the results from its Phase 2a safety trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD and

IVERIC bio Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)

By |2019-02-11T13:21:58+00:00Oct 31, 2018 |Uncategorized|

- IVERIC bio Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease - NEW YORK--(BUSINESS WIRE)--Oct. 31, 2018-- IVERIC bio Corporation (NASDAQ:ISEE) announced today that it has entered into an exclusive option agreement with the University of Pennsylvania (Penn) and the University of

IVERIC bio Reports Third Quarter 2018 Financial and Operating Results

By |2019-02-11T13:22:03+00:00Oct 31, 2018 |Uncategorized|

- Conference Call and Webcast to Discuss Q3 2018 Results and Two Pipeline Deals Announced Today - (Conference Call:Today, October 31, 2018, at 8:00 a.m. ET) NEW YORK--(BUSINESS WIRE)--Oct. 31, 2018-- IVERIC bio Corporation (Nasdaq:ISEE) today announced financial and operating results for the third quarter ended September 30, 2018 and provided a business update. “During 2018 IVERIC bio made significant